New statins and new doses of older statins.
The need for greater reductions in LDL cholesterol, although remaining to be proven as clinically beneficial, continues to drive the development of either higher doses of currently approved and marketed statins or the development of new, more effective agents.
Stein
E A
EA
Medical Research Laboratories, 2 Tesseneer, Highland Heights, KY 41076, USA. esteinmrl@aol.com
D000069059:Atorvastatin; D008078:Cholesterol, LDL / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage; D005464:Fluorobenzenes / Q000008:administration & dosage; D000077340:Fluvastatin; D006538:Heptanoic Acids / Q000008:administration & dosage; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D007211:Indoles / Q000008:administration & dosage; D008148:Lovastatin / Q000008:administration & dosage; D017035:Pravastatin / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D011743:Pyrimidines; D011758:Pyrroles / Q000008:administration & dosage; D000068718:Rosuvastatin Calcium; D019821:Simvastatin / Q000008:administration & dosage; D013449:Sulfonamides
D008078:Cholesterol, LDL; D005229:Fatty Acids, Monounsaturated; D005464:Fluorobenzenes; D006538:Heptanoic Acids; D000960:Hypolipidemic Agents; D007211:Indoles; D011725:Pyridines; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; D000077340:Fluvastatin; D000068718:Rosuvastatin Calcium; D008148:Lovastatin; D000069059:Atorvastatin; D019821:Simvastatin; C086276:cerivastatin; D017035:Pravastatin